BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,089,838 | +104.3% | 130,676 | +181.2% | 0.04% | +40.0% |
| Q4 2022 | $533,567 | -22.8% | 46,478 | -15.3% | 0.02% | +13.6% |
| Q3 2022 | $691,000 | +9.0% | 54,871 | -6.4% | 0.02% | +22.2% |
| Q2 2022 | $634,000 | -31.2% | 58,645 | +4.7% | 0.02% | 0.0% |
| Q1 2022 | $921,000 | +22.8% | 56,014 | +3.0% | 0.02% | +20.0% |
| Q4 2021 | $750,000 | -20.1% | 54,383 | -16.7% | 0.02% | -16.7% |
| Q3 2021 | $939,000 | +15.6% | 65,312 | +24.6% | 0.02% | +38.5% |
| Q2 2021 | $812,000 | +49.8% | 52,412 | -3.4% | 0.01% | +30.0% |
| Q1 2021 | $542,000 | -15.8% | 54,272 | -36.8% | 0.01% | -28.6% |
| Q4 2020 | $644,000 | +69.9% | 85,880 | -13.2% | 0.01% | +16.7% |
| Q3 2020 | $379,000 | +56.6% | 98,949 | +103.3% | 0.01% | +33.3% |
| Q2 2020 | $242,000 | – | 48,675 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |